Clinical value detection of testicular microlithiasis and recently discovered markers in testicular germ–cell tumors


А. В. Сакало


Testicular germ-cell tumors (TGCTs) are the most frequent malignant tumors in men 20–40 years of age and the most frequent cause of death in this age group. TGCTs consist of two major groups: seminomas and nonseminomatous germcell tumors (NSGCTs). NSGCTs can be further divided into embryonic carcinoma, teratoma, yolk sac tumor, and choriocarcinoma, which differ in therapy, prognosis, but all show characteristics of the primordial germ cells. New biomarkers potentially represent novel molecular targets for treatment. The role of microRNA is highlighted as molecular prognostic factor in TGCT. Testicular microlithiasis (TM) often detected during examination among men with TGCTs, cryptorchidism, infertility, testicular atrophy and dysgenesis. Patients with TM form a group of risk of development of TGCTs. Also at high risk are patients with infertility, bilateral TM, atrophic and undescended testes and history of TGCTs.


How to Cite
Сакало, А. В. (2018). Clinical value detection of testicular microlithiasis and recently discovered markers in testicular germ–cell tumors. Health of Man, (2), 27–30.
Topical issues
Author Biography

А. В. Сакало, State Institution «Institute of Urology of NAMS of Ukraine»

Anatolii V. Sakalo,

Division of Urologic Oncology


Richenberg J. Testicular microlithiasis imaging and follow-up: guidelines of the ESUR scrotal imaging subcommittee / J. Richenberg, J. Belfield, P. Ramchandani [et al.] // Eur. Rad. – 2015. – P. 323–330.

Pedersen M. Testicular microlithiasis and testicular cancer: review of the literature / M. Pedersen, S. Rafaelsen, H. Moller [et al.] // Int. Urol. Nephrol. – 2016. – 7. – P. 1079–86.

Miller F.N. Does testicular microlithiasis matter? A review / F.N. Miller [et al.] // Clin. Radiol. – 2002. – 57. – P. 883–90.

Nord C. Gonadal hormones in long term survivors 10 years after treatment for unilateral testicular cancer / C. Nord [et al.] // Eur. Urol. – 2003. – 322–8.

Gilligan TD. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors / TD. Gilligan, J. Seidenfeld, EM. Basch [et al.] // J.Clin.Oncol. – 2010. – 20. – P. 3388–404.

Barlow L. Serum tumor markers in the evaluation of male germ cell tumors / L. Barlow, G. Badalato, J. McKiernan // Nat Rev Urol. – 2010. – 7 (11). – P. 610–7.

Krege S. The role of tumour markers in diagnosis and management of testicular germ cell tumours / S. Krege, P. Alberts, A. Heidenreich // Urologe A. – 2011. – 3. – P. 313–21.

Ulbright TM. The most common, clinically significant misdiagnoses in testicular tumor pathology, and how to avoid them / TM. Ulbright // Adv Anat Pathol. – 2008. – 1. – P. 18–27.

Cleynen I. The HMGA proteins: a myriad of functions (Review) / I. Cleynen, W. Van de Ven // Int J Oncol. – 2008. – 2. – P. 289–305.

Pallante P. High mobility group a proteins as tumor markers / P. Pallante, R. Sepe, F. Puca [et al.] // Front Med. – 2015. – 2. – P. 15.

Barbagallo F. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas / F. Barbagallo, M. Paronetto, R. Franco [et al.] // J Pathol. – 2009. – 217 (3). – P. 431–41.

Looijenga L. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors / L. Looijenga, H. Stoop, H. de Leeuw [et al.] // Cancer Res. – 2003. – 63 (9). – P. 2244–50.

Gillis A. Expression and interdependencies of pluripotency factors LIN28, OCT3/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis / A. Gillis, H. Stoop, K. Biermann [et al.] // Int J Androl. – 2011. – 34. e160–74.

Dieckmann K. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours / K. Dieckmann, M. Spiekermann, T. Balks [et al.] // Br J Cancer. – 2012. – 10. – P. 1754–60.

Spiekermann M. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker / M. Spiekermann, G. Belge, N. Winter [et al.] // Andrology. – 2015. – 1. – P. 78–84.

Rounge T. Profiling of the small RNA populations in human testicular germ cell tumors shows global loss of piRNAs / T. Rounge, K. Furu, R. Skotheim [et al.] // Mol Cancer. – 2015. – 14. – P. 153.

Syring I. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer / I. Syring, J. Bartels, S. Holdenrieder [et al.] // J Urol. – 2015. – 1. – P. 331–337.

Catto J. MicroRNA in prostate, bladder, and kidney cancer: a systematic review / J. Catto, A. Alcaraz, A. Bjartell [et al.] // Eur Urol. – 2011. – 5. – P. 671–81.

Gillis A. Targeted serum miRNA(TSmiR) test for diagnosis and follow-up of testicular germ cell cancer patients: a proof of principle / A. Gillis, M. Rijlaarsdam, R. Eini [et al.] // Mol Oncol. – 2013. – 6. – P. 1083–92.

Palmer R. Children’s Cancer and Leukaemia Group. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets / R. Palmer, M. Murray, H. Saini [et al.] // Cancer Res. – 2010. – 7. – P. 2911–23.

Ruf C. Small RNAs in the peripheral blood discriminate metastasized from nonmetastasized seminoma / C. Ruf, D. Dinger, M. Port [et al.] // Mol Cancer. – 2014. – 6. – 13. – P. 47.

Chieffi P. Recent advances in molecular and cell biology of testicular germcell tumors / P. Chieffi // Int Rev Cell Mol Biol. – 2014. – 312. – P. 79–100.

Chieffi P. An up-date on newly discovered immunohistochemical biomarkers for the diagnosis of human testicular germ cell tumors / P. Chieffi, S. Chieffi // Histol Histopathol. – 2014. – 29 (8). – P. 999–1006